At Northwell Health, Lake Success, New York, Alisha Oropallo, MD, FACS, is Director, Northshore/LIJ Wound Healing Center and Hyperbarics; Ashley Goodwin, MD, is Visiting Scholar, Department of Surgery; MaKenzie Morrissey, MD, is Visiting Scholar, Department of Surgery; Christina Del Pin, MD, FACS, is Attending Surgeon, Department of Surgery; and Amit Rao, MD, is Research Coordinator, Department of Surgery. The authors have disclosed no financial relationships related to this article. Submitted March 2, 2020; accepted in revised form May 4, 2020.
Adv Skin Wound Care. 2021 Apr 1;34(4):1-7. doi: 10.1097/01.ASW.0000734388.08779.e8.
To discuss human amnion chorion (placental) membrane allograft (HACMA) use for the treatment of chronic diabetic foot ulcers (DFUs) and to evaluate the effectiveness, cost, and product waste of this therapy.
PubMed, Cochrane, and OVID databases.
Twenty-four articles pertaining to HACMA and DFUs published from 2016 to 2020 were selected.
The data collected included type of wound care product, study design, study size, baseline size of DFU, cost, product wastage, number of applications, and wound healing outcomes.
Human amnion chorion membrane allografts in the treatment of chronic DFUs have led to a reduction in healing time and increased the overall percentage of healing, making them more effective in treating DFUs compared with standard of care. These products are offered in multiple sizes with various shelf lives and methods of storage, making them accessible, easy to use, less wasteful, and lower in cost compared with other commercially available products. Promising evidence demonstrates that HACMAs are beneficial in treating complex, high-grade DFUs with exposed tendon or bone.
Human amnion chorion membrane allografts are effective in treating chronic DFUs with a greater percentage of complete wound closure and a reduction in healing time versus standard of care.
讨论人羊膜绒毛膜（胎盘）膜同种异体移植物（HACMA）在治疗慢性糖尿病足溃疡（DFUs）中的应用，并评估该疗法的有效性、成本和产品浪费。
PubMed、Cochrane 和 OVID 数据库。
选择了 2016 年至 2020 年期间发表的 24 篇关于 HACMA 和 DFUs 的文章。
收集的数据包括伤口护理产品类型、研究设计、研究规模、DFU 基线大小、成本、产品浪费、应用次数和伤口愈合结果。
人羊膜绒毛膜膜同种异体移植物治疗慢性 DFUs 可缩短愈合时间，增加总体愈合百分比，与标准治疗相比，治疗 DFUs 更有效。这些产品有多种尺寸、保质期和储存方法，与其他市售产品相比，它们更容易获得、使用方便、浪费少、成本低。有有前景的证据表明，HACMA 有利于治疗伴有肌腱或骨外露的复杂、高级别 DFUs。
与人羊膜绒毛膜膜同种异体移植物相比，HACMA 治疗慢性 DFUs 更有效，完全愈合的百分比更高，愈合时间更短。
